Andrew Brennan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Andrew Brennan has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Jody M. Mason
Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science Institute for Molecular Bioscience The University of Queensland Brisbane Queensland Australia
7 shared publications - Daniel Scott
School of Life Sciences, Queen's Medical Centre University of Nottingham Nottingham NG7 2UH UK
1 shared publication - Huw E. L. Williams
University of Nottingham
1 shared publication - James T. Leech
University of Kent
1 shared publication Jed Long
Centre for Biomolecular Sciences, School of Chemistry, University Park, University of Nottingham, Nottingham NG7 2RD, UK
1 shared publicationKeith W. Vance
Department of Life Sciences, University of Bath, Bath BA2 7AY, UK
1 shared publication
Latest Publications
- Open Access
- 27 July 2026
- Published by Springer Nature in Communications Chemistry
- Vol. 9 (1)
Intracellular bismuth coordination of peptides and miniproteins enables functional screening of stable cyclic architectures
Cyclisation of peptides and proteins is a powerful chemical strategy to enhance molecular stability and functional efficacy, yet executing coordination chemistry within living cells remains challenging. Bismuth(III) coordination represents a particularly compact and chemoselective cyclisation modality, yet to date has remained confined to in vitro or phage-based screening systems. Here we report bismuth(III)-thiolate coordination chemistry within living cells during recombinant expression in E. coli , enabling intracellular cyclisation of peptides and miniproteins. Supplementation of growth media with bismuth salts enabled efficient intracellular coordination of either three or six cysteine residues, yielding bicyclic and tetracyclic architectures with minimal cellular toxicity. Bis-bismuth coordination generated a tetracyclic miniprotein with enhanced thermal and serum stability, representing a level of intracellular structural reinforcement not previously accessible. To validate this chemistry in a functional selection format, we integrated intracellular bismuth coordination with an alpha-synuclein protein-fragment complementation assay, screening a genetically encoded library to enrich a bismuth-constrained bicyclic peptide that reduced α-synuclein aggregation. Intracellular bismuth coordination therefore enables peptide and miniprotein constraint during expression, preserving genotype–phenotype linkage and expanding the topological space accessible to live-cell screening platforms.
- 27 July 2026
- Published by Springer Nature in Communications Chemistry
- Vol. 9 (1)
Open AccessIntracellular bismuth coordination of peptides and miniproteins enables functional screening of stable cyclic architectures
Cyclisation of peptides and proteins is a powerful chemical strategy to enhance molecular stability and functional efficacy, yet executing coordination chemistry within living cells remains challenging. Bismuth(III) coordination represents a particularly compact and chemoselective cyclisation modality, yet to date has remained confined to in vitro or phage-based screening systems. Here we report bismuth(III)-thiolate coordination chemistry within living cells during recombinant expression in E. coli , enabling intracellular cyclisation of peptides and miniproteins. Supplementation of growth media with bismuth salts enabled efficient intracellular coordination of either three or six cysteine residues, yielding bicyclic and tetracyclic architectures with minimal cellular toxicity. Bis-bismuth coordination generated a tetracyclic miniprotein with enhanced thermal and serum stability, representing a level of intracellular structural reinforcement not previously accessible. To validate this chemistry in a functional selection format, we integrated intracellular bismuth coordination with an alpha-synuclein protein-fragment complementation assay, screening a genetically encoded library to enrich a bismuth-constrained bicyclic peptide that reduced α-synuclein aggregation. Intracellular bismuth coordination therefore enables peptide and miniprotein constraint during expression, preserving genotype–phenotype linkage and expanding the topological space accessible to live-cell screening platforms.
- Open Access
- 3 March 2026
- Published by Elsevier in Cell Chemical Biology
- Vol. 33 (3) , 409-423.e7
Intracellular cyclization-coupled peptide library screening yields potent transcription factor antagonists
- 3 March 2026
- Published by Elsevier in Cell Chemical Biology
- Vol. 33 (3) , 409-423.e7
Open AccessIntracellular cyclization-coupled peptide library screening yields potent transcription factor antagonists
- Open Access
Intracellular Bismuth Coordination of Peptides and Miniproteins
Cyclisation of peptides has emerged as a powerful methodology to enhance molecular stability and functional efficacy. Bismuth(III) coordination represents a particularly compact and chemoselective cyclisation modality, yet to date has remained confined to in vitro or phage-based systems. Here we report the first example of bismuth-mediated peptide and minprotein cyclisation occurring within living cells, achieved directly during recombinant expression in E. coli. Supplementation of growth media with bismuth salts enables efficient intracellular coordination of either three or six cysteine residues, yielding bicyclic and tetracyclic architectures with minimal cellular toxicity. Bis-bismuth coordination generated a tetra-cyclic minprotein with exceptional thermal and serum stability, representing a level of intracellular structural reinforcement not previously accessible. This chemistry enables the intracellular constraint of peptides and proteins and is directly compatible with genetically encoded peptide and miniprotein libraries, establishing bismuth coordination as a compact and robust modality for live-cell molecular screening.
Open AccessIntracellular Bismuth Coordination of Peptides and Miniproteins
Cyclisation of peptides has emerged as a powerful methodology to enhance molecular stability and functional efficacy. Bismuth(III) coordination represents a particularly compact and chemoselective cyclisation modality, yet to date has remained confined to in vitro or phage-based systems. Here we report the first example of bismuth-mediated peptide and minprotein cyclisation occurring within living cells, achieved directly during recombinant expression in E. coli. Supplementation of growth media with bismuth salts enables efficient intracellular coordination of either three or six cysteine residues, yielding bicyclic and tetracyclic architectures with minimal cellular toxicity. Bis-bismuth coordination generated a tetra-cyclic minprotein with exceptional thermal and serum stability, representing a level of intracellular structural reinforcement not previously accessible. This chemistry enables the intracellular constraint of peptides and proteins and is directly compatible with genetically encoded peptide and miniprotein libraries, establishing bismuth coordination as a compact and robust modality for live-cell molecular screening.
- Open Access
- 30 October 2025
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 5 (11) , 5337-5345
Enhancing the Efficacy, Utility, and Throughput of the Transcription Block Survival Peptide Library Screening Platform
Genetically encoded peptide library screening is a powerful strategy for discovering inhibitors of protein–protein and protein–DNA interactions. The Transcription Block Survival (TBS) assay enables the in vivo selection of peptides that antagonize transcription factor (TF) function by linking the inhibition of DNA binding to E. coli survival. However, previous TBS implementations required laborious re-engineering of the mDHFR coding region for each new target, limiting utility. Here, we present an enhanced and streamlined TBS platform that increases throughput, simplifies target switching, and improves selection stringency. By relocating TF DNA-binding sites from within the mDHFR coding sequence into the mDHFR 5′-promoter/untranslated region, we preserve mDHFR folding and function, enabling rapid interchange of TF targets without the need for extensive construct redesign. We validated this system using three distinct TF targets, CREB1, ATF2, and DLX5, and two distinct consensus sites, demonstrating robust transcriptional block upon TF binding and efficient growth rescue upon peptide-mediated antagonism. Importantly, we expand the platform to accommodate full-length TFs, as exemplified by DLX5, allowing selection against biologically relevant full-length, multidomain proteins without immobilization or tags. TBS continues to function exclusively by selecting for the disruption of protein–DNA binding, ensuring mechanistic precision. Using this optimized TBS system, we successfully screened an 11.3-million-member peptide library to identify a potent antagonist of ATF2-CRE DNA binding within three months. This next generation TBS platform significantly improves screening efficiency and selection pressure while maintaining high biological relevance, providing a versatile and scalable tool for discovering functional peptide inhibitors of protein–DNA interactions with therapeutic potential.
- 30 October 2025
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 5 (11) , 5337-5345
Open AccessEnhancing the Efficacy, Utility, and Throughput of the Transcription Block Survival Peptide Library Screening Platform
Genetically encoded peptide library screening is a powerful strategy for discovering inhibitors of protein–protein and protein–DNA interactions. The Transcription Block Survival (TBS) assay enables the in vivo selection of peptides that antagonize transcription factor (TF) function by linking the inhibition of DNA binding to E. coli survival. However, previous TBS implementations required laborious re-engineering of the mDHFR coding region for each new target, limiting utility. Here, we present an enhanced and streamlined TBS platform that increases throughput, simplifies target switching, and improves selection stringency. By relocating TF DNA-binding sites from within the mDHFR coding sequence into the mDHFR 5′-promoter/untranslated region, we preserve mDHFR folding and function, enabling rapid interchange of TF targets without the need for extensive construct redesign. We validated this system using three distinct TF targets, CREB1, ATF2, and DLX5, and two distinct consensus sites, demonstrating robust transcriptional block upon TF binding and efficient growth rescue upon peptide-mediated antagonism. Importantly, we expand the platform to accommodate full-length TFs, as exemplified by DLX5, allowing selection against biologically relevant full-length, multidomain proteins without immobilization or tags. TBS continues to function exclusively by selecting for the disruption of protein–DNA binding, ensuring mechanistic precision. Using this optimized TBS system, we successfully screened an 11.3-million-member peptide library to identify a potent antagonist of ATF2-CRE DNA binding within three months. This next generation TBS platform significantly improves screening efficiency and selection pressure while maintaining high biological relevance, providing a versatile and scalable tool for discovering functional peptide inhibitors of protein–DNA interactions with therapeutic potential.
- Open Access
Enhancing the efficacy, utility and throughput of the Transcription Block Survival peptide library screening platform
Genetically encoded peptide library screening is a powerful strategy for discovering inhibitors of protein-protein and protein-DNA interactions. The Transcription Block Survival (TBS) assay enables the in vivo selection of peptides that antagonise transcription factor (TF) binding by linking inhibition of DNA-binding to E . coli survival. However, previous TBS implementations required laborious re-engineering of the mDHFR coding region for each new target, limiting utility. Here, we present an enhanced and streamlined TBS platform that increases throughput, simplifies target switching and improves selection stringency. By relocating TF-DNA binding sites from within the mDHFR coding sequence into the mDHFR 5’-promoter/untranslated region, we preserve mDHFR folding and function, enabling rapid interchange of TF targets without the need for extensive construct redesign. We validated this system using three distinct TF targets, CREB1, ATF2 and DLX5, and two distinct consensus sites, demonstrating robust transcriptional block upon TF binding and efficient growth rescue upon peptide-mediated antagonism. Importantly, we expand the platform to accommodate full-length TFs, as exemplified by DLX5, allowing selection against biologically relevant multi-domain proteins. TBS continues to function exclusively by selecting for disruption of protein-DNA binding, ensuring mechanistic precision. Using this optimised TBS system, we successfully screened an 11.3-million-member peptide library to identify a potent antagonist of ATF2-CRE DNA binding within three months. This next generation TBS-platform dramatically improves screening efficiency and selection pressure while maintaining high biological relevance, providing a versatile and scalable tool for discovering functional peptide inhibitors of protein-DNA interactions with therapeutic potential.
Open AccessEnhancing the efficacy, utility and throughput of the Transcription Block Survival peptide library screening platform
Genetically encoded peptide library screening is a powerful strategy for discovering inhibitors of protein-protein and protein-DNA interactions. The Transcription Block Survival (TBS) assay enables the in vivo selection of peptides that antagonise transcription factor (TF) binding by linking inhibition of DNA-binding to E . coli survival. However, previous TBS implementations required laborious re-engineering of the mDHFR coding region for each new target, limiting utility. Here, we present an enhanced and streamlined TBS platform that increases throughput, simplifies target switching and improves selection stringency. By relocating TF-DNA binding sites from within the mDHFR coding sequence into the mDHFR 5’-promoter/untranslated region, we preserve mDHFR folding and function, enabling rapid interchange of TF targets without the need for extensive construct redesign. We validated this system using three distinct TF targets, CREB1, ATF2 and DLX5, and two distinct consensus sites, demonstrating robust transcriptional block upon TF binding and efficient growth rescue upon peptide-mediated antagonism. Importantly, we expand the platform to accommodate full-length TFs, as exemplified by DLX5, allowing selection against biologically relevant multi-domain proteins. TBS continues to function exclusively by selecting for disruption of protein-DNA binding, ensuring mechanistic precision. Using this optimised TBS system, we successfully screened an 11.3-million-member peptide library to identify a potent antagonist of ATF2-CRE DNA binding within three months. This next generation TBS-platform dramatically improves screening efficiency and selection pressure while maintaining high biological relevance, providing a versatile and scalable tool for discovering functional peptide inhibitors of protein-DNA interactions with therapeutic potential.
- Open Access
- 17 March 2025
- Published by Wiley in Advanced Science
- Vol. 12 (18) , e2416963
An Intracellular Peptide Library Screening Platform Identifies Irreversible Covalent Transcription Factor Inhibitors
The development of an intracellular peptide library screening platform is described to identify covalent transcription factor (TF) antagonists. The Transcription Block Survival (TBS) assay and subsequent hit refinement previously produced potent but reversible antagonists of the oncogenic TF cJun. TBS moves beyond a target binding readout to ensure loss of TF function by blocking TF‐DNA binding. Here, the TBS methodology is significantly expanded to identify covalent and highly selective inhibitors. A 131,072‐member library is probed containing a Cys option at nine positions within a non‐reducing cell line. This identified a single Cys residue with the appropriate geometry for disulphide bond formation with cJun C269 in its DNA binding domain. The selection of a unique Cys in the antagonist indicates both target shutdown and concomitant disulphide formation in a single step, resulting in increased potency. Substituting Cys with an electrophile generates an irreversible yet highly selective covalent cJun inhibitor capable of penetrating human melanoma cells in culture and depleting oncogenic cJun levels to inhibit cell viability, with enhanced efficacy compared to a previous cJun‐targeting peptide. This enhanced covalent‐TBS screening pipeline provides a robust approach to profile target protein surfaces for ligandable cysteines, producing covalent and selective antagonists with appropriately positioned warheads.
- 17 March 2025
- Published by Wiley in Advanced Science
- Vol. 12 (18) , e2416963
Open AccessAn Intracellular Peptide Library Screening Platform Identifies Irreversible Covalent Transcription Factor Inhibitors
The development of an intracellular peptide library screening platform is described to identify covalent transcription factor (TF) antagonists. The Transcription Block Survival (TBS) assay and subsequent hit refinement previously produced potent but reversible antagonists of the oncogenic TF cJun. TBS moves beyond a target binding readout to ensure loss of TF function by blocking TF‐DNA binding. Here, the TBS methodology is significantly expanded to identify covalent and highly selective inhibitors. A 131,072‐member library is probed containing a Cys option at nine positions within a non‐reducing cell line. This identified a single Cys residue with the appropriate geometry for disulphide bond formation with cJun C269 in its DNA binding domain. The selection of a unique Cys in the antagonist indicates both target shutdown and concomitant disulphide formation in a single step, resulting in increased potency. Substituting Cys with an electrophile generates an irreversible yet highly selective covalent cJun inhibitor capable of penetrating human melanoma cells in culture and depleting oncogenic cJun levels to inhibit cell viability, with enhanced efficacy compared to a previous cJun‐targeting peptide. This enhanced covalent‐TBS screening pipeline provides a robust approach to profile target protein surfaces for ligandable cysteines, producing covalent and selective antagonists with appropriately positioned warheads.
- Open Access
- 18 December 2021
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 298 (2) , 101514
An ALS-associated variant of the autophagy receptor SQSTM1/p62 reprograms binding selectivity toward the autophagy-related hATG8 proteins
- 18 December 2021
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 298 (2) , 101514
Open AccessAn ALS-associated variant of the autophagy receptor SQSTM1/p62 reprograms binding selectivity toward the autophagy-related hATG8 proteins
- Open Access
- 24 January 2020
- Published by Cold Spring Harbor Laboratory in bioRxiv
Single molecule imaging reveals the collective and independent search mechanisms of cFos and cJun on DNA
AP-1 proteins are members of the basic leucine zipper (bZIP) family of dimeric transcription factors, which facilitate a multitude of cellular processes, but are primarily known for their oncogenic potential in several cancer types. The oncogenic transcription factor AP-1 binds a specific DNA target site (5’TCA[G/C]TGA), however the physical mechanism of how this is achieved has not been determined. The archetypal AP-1 complex is formed by cFos and cJun, which heterodimerize via their leucine zipper domains. We investigated the DNA-binding bZIP domains of AP-1 interacting with DNA tightropes using real-time single molecule fluorescence imagingin vitro. We find that AP-1 bZIP domains comprising cFos:cJun and cJun:cJun rapidly scan DNA using a 1D diffusional search with average diffusion constants of 0.14 μm2s−1and 0.26 μm2s−1respectively. We also report for the first time that cFos is able to bind to and diffuse on DNA (0.29 μm2s−1) as a mixed population of monomers and homodimers, despite previous studies suggesting that it is incapable of independent DNA binding. Additionally, we note increased pause lifetimes for the cFos:cJun heterodimer compared to the cJun:cJun homodimer, and were able to detect distinct pausing behaviours within diffusion data. Understanding how cFos:cJun and other transcription factors identify their targets is highly relevant to the development of new therapeutics which target DNA binding proteins using these search mechanisms.
- 24 January 2020
- Published by Cold Spring Harbor Laboratory in bioRxiv
Open AccessSingle molecule imaging reveals the collective and independent search mechanisms of cFos and cJun on DNA
AP-1 proteins are members of the basic leucine zipper (bZIP) family of dimeric transcription factors, which facilitate a multitude of cellular processes, but are primarily known for their oncogenic potential in several cancer types. The oncogenic transcription factor AP-1 binds a specific DNA target site (5’TCA[G/C]TGA), however the physical mechanism of how this is achieved has not been determined. The archetypal AP-1 complex is formed by cFos and cJun, which heterodimerize via their leucine zipper domains. We investigated the DNA-binding bZIP domains of AP-1 interacting with DNA tightropes using real-time single molecule fluorescence imagingin vitro. We find that AP-1 bZIP domains comprising cFos:cJun and cJun:cJun rapidly scan DNA using a 1D diffusional search with average diffusion constants of 0.14 μm2s−1and 0.26 μm2s−1respectively. We also report for the first time that cFos is able to bind to and diffuse on DNA (0.29 μm2s−1) as a mixed population of monomers and homodimers, despite previous studies suggesting that it is incapable of independent DNA binding. Additionally, we note increased pause lifetimes for the cFos:cJun heterodimer compared to the cJun:cJun homodimer, and were able to detect distinct pausing behaviours within diffusion data. Understanding how cFos:cJun and other transcription factors identify their targets is highly relevant to the development of new therapeutics which target DNA binding proteins using these search mechanisms.